{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/urinary-tract-infection-lower-women/prescribing-information/nitrofurantoin/","result":{"pageContext":{"chapter":{"id":"76a10025-1806-5d3b-96b0-72401241a768","slug":"nitrofurantoin","fullItemName":"Nitrofurantoin","depth":2,"htmlHeader":"<!-- begin field 4b1dfd62-8415-44df-892c-a71c00ab7891 --><h2>Nitrofurantoin</h2><!-- end field 4b1dfd62-8415-44df-892c-a71c00ab7891 -->","summary":"","htmlStringContent":"<!-- begin item 422dd2c9-a1fb-403f-8a6a-a71c00ab796b --><!-- end item 422dd2c9-a1fb-403f-8a6a-a71c00ab796b -->","topic":{"id":"4205a2dd-1d74-53f2-90f4-5239307d2883","topicId":"7e36f7cd-e707-44db-a683-f4197a84b187","topicName":"Urinary tract infection (lower) - women","slug":"urinary-tract-infection-lower-women","lastRevised":"Last revised in October 2020","chapters":[{"id":"96f75303-a8ae-50a0-9d5c-e5a9b96e67f1","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"cafb451d-db29-558a-a6cc-20d82dde3df9","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"14a65465-7aa4-5024-bb53-b3b2099b526a","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"7b90ea0f-0f86-5457-965d-930656bd2f02","slug":"changes","fullItemName":"Changes"},{"id":"4f3fd7bc-437b-509c-9a2d-5318de2b1e8b","slug":"update","fullItemName":"Update"}]},{"id":"850e1193-41eb-50b7-b401-ac0396c6e585","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"18c79474-b4ac-50cd-801a-3738d79a1159","slug":"goals","fullItemName":"Goals"},{"id":"24f4bdf7-0aa4-5f6b-a117-2c3a7da00984","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"6b590746-634f-5a0c-b995-5f98bd9c6f0d","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"4c2be4f2-9e65-53d3-8ff6-7534932e7dc6","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"835cf60d-f7b4-57b8-97ee-607930381034","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"a526f295-371c-52d5-bd46-93333947aade","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"28adde3c-64d3-5e21-8797-08c56ab570c5","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"4a732f85-1f37-5288-a872-611c3528c53e","slug":"definition","fullItemName":"Definition"},{"id":"8e922399-2c9d-5777-9660-944733f631f5","slug":"causes","fullItemName":"Causes"},{"id":"8fa46cfc-d97b-5218-847f-9553a7ce2854","slug":"prevalence","fullItemName":"Prevalence"},{"id":"c9ad7aa8-f54d-55a8-b6f1-804d616de2b4","slug":"prognosis","fullItemName":"Prognosis"},{"id":"a176b8d4-1d8f-5f62-935e-4f6fc4696153","slug":"complications","fullItemName":"Complications"}]},{"id":"03286f6f-e3d8-5889-8453-1db9ffb07914","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ec9700ef-7ba2-524e-868a-3dc60b345625","slug":"when-to-suspect-uti","fullItemName":"When to suspect UTI"},{"id":"182ae581-d75a-507d-8146-e0d7d26dcad8","slug":"assessment","fullItemName":"Assessment"},{"id":"5dfac6cd-ec1e-5d54-98a4-a65cf57457d9","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"6d45128d-30db-5879-917a-4a6e682fa7e9","fullItemName":"Management","slug":"management","subChapters":[{"id":"a72789b5-d51e-5516-8ab1-942aae1e0fe8","slug":"uti-no-visible-haematuria-not-pregnant-or-catheterized","fullItemName":"Scenario: UTI  (no visible haematuria, not pregnant or catheterized)"},{"id":"91dbd4da-8761-5e78-9eb2-a773cc7d2764","slug":"uti-with-visible-or-non-visible-haematuria","fullItemName":"Scenario: UTI  with visible or non-visible haematuria"},{"id":"3e093a06-3197-58a5-8c61-94586835adba","slug":"recurrent-uti-no-visible-haematuria-not-pregnant-or-catheterized","fullItemName":"Scenario: Recurrent UTI  (no visible haematuria, not pregnant or catheterized)"},{"id":"09df152e-ea9c-51c1-917c-5c4c01ab2fc8","slug":"uti-in-pregnancy-no-visible-haematuria","fullItemName":"Scenario: UTI in pregnancy  no visible haematuria"},{"id":"6d0e09de-6e28-53df-b01b-55fc899c0dd7","slug":"asymptomatic-bacteriuria-in-pregnancy","fullItemName":"Scenario: Asymptomatic bacteriuria in pregnancy"},{"id":"07efc80a-4963-5037-a8f2-c5b63d298205","slug":"uti-with-catheter-no-haematuria","fullItemName":"Scenario: UTI with catheter  no haematuria"}]},{"id":"7a32c4da-f7b1-5664-92e2-e1fdeca6361a","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"b42d0bbc-d0ac-52c7-83bf-5fc7a76a38dc","slug":"trimethoprim","fullItemName":"Trimethoprim"},{"id":"76a10025-1806-5d3b-96b0-72401241a768","slug":"nitrofurantoin","fullItemName":"Nitrofurantoin"},{"id":"625120b5-8124-549f-b13c-8b37bea158ff","slug":"pivmecillinam","fullItemName":"Pivmecillinam"},{"id":"bae5a7ea-ae42-56ba-82cc-74cbc655059f","slug":"fosfomycin","fullItemName":"Fosfomycin"},{"id":"e8dc8860-ec55-59c6-96c0-805260cb7172","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"e5121975-a684-5651-bf41-c324e815c0f5","slug":"cefalexin","fullItemName":"Cefalexin"}]},{"id":"332fba52-4a32-56f0-b721-29ac73f73e6d","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"8f34f8fc-4bd2-54e3-87f0-a4a1394f3891","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"9b392302-d709-5520-a890-25e10021e12b","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0d4bbe1a-f3f6-523c-85c0-1fae02dd5b27","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"84ca6e0f-7674-5f70-b099-406d5c783d89","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"4ed139aa-715a-523d-8c0a-8f4e167d29df","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"067e363b-53be-5584-a0e9-2bf38e519877","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"045ecabb-df97-5df3-b561-ecddea4b7b17","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"7a32c4da-f7b1-5664-92e2-e1fdeca6361a","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"80c3b39f-0796-5bcb-801a-7315d2d1370f","slug":"nitrofurantoin","fullItemName":"Nitrofurantoin","depth":3,"htmlHeader":"<!-- begin field a83f567e-9b8d-406b-a68a-a71c00ac3fdb --><h3>Nitrofurantoin</h3><!-- end field a83f567e-9b8d-406b-a68a-a71c00ac3fdb -->","summary":"","htmlStringContent":"<!-- begin item 7ad0b6b8-162a-4f7e-a3df-a71c00ac3fe5 --><!-- begin field 22e6a413-a978-4ea4-b337-a71c00ac3fdb --><p><strong>Cautions and contraindications</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">MHRA, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">Arnold, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">ACOG, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">BNF 76, 2018</a>]</p><ul><li><strong>Do not prescribe nitrofurantoin in infants aged less than 3 months, or people with:</strong><ul><li>Hypersensitivity to the active substance, other nitrofurans or to any of the excipients.</li><li>Acute porphyria.</li><li>Renal impairment — estimated glomerular filtration rate (eGFR) less than 45 mL/minute/1.73 m2.<ul><li>A short course (3–7 days) may be considered with caution in certain people if the eGFR is 30–44 mL/minute/1.73 m2 and a urinary tract infection has suspected or proven multi-drug resistance, when the benefits of nitrofurantoin are considered to outweigh the risks of adverse effects.</li></ul></li><li>Glucose-6-phosphate dehydrogenase deficiency.</li><li>At term in pregnancy because of the risk of neonatal haemolysis.</li></ul></li><li><strong>Prescribe nitrofurantoin with caution in people with:</strong><ul><li>Peripheral neuropathy or susceptibility to peripheral neuropathy — treatment should be stopped at the first signs of neural involvement (paraesthesiae).</li><li>Anaemia, diabetes mellitus, electrolyte imbalance, debilitating conditions, pulmonary disease, hepatic impairment, renal impairment and vitamin B (particularly folate) deficiency since these conditions may enhance the occurrence of peripheral neuropathy.</li></ul></li></ul><p><strong>Adverse effects </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">Arnold, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">Muller, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">BNF 76, 2018</a>]</p><ul><li>Blood disorders — agranulocytosis, leucopenia, granulocytopenia, haemolytic anaemia, thrombocytopenia, megaloblastic anaemia, glucose-6-phosphate dehydrogenase deficiency anaemia, and eosinophilia (rare).</li><li>Gastrointestinal — nausea and anorexia.<ul><li>Vomiting, abdominal pain, and diarrhoea are less common.</li><li>Hepatobiliary disorders — chronic hepatitis, cholestatic jaundice (rarely).</li></ul></li><li>Respiratory — acute pulmonary reactions may occur within the first week of treatment, and are manifested by: fever, chills, cough, chest pain, dyspnoea, and eosinophilia. Reversible on stopping treatment.<ul><li>Rarely: chronic pulmonary reactions occur in people who have received continuous therapy for six months or longer. It is more common in the elderly.</li></ul></li><li>Nervous system — peripheral neuropathy (infrequent).<ul><li>Less frequently: depression, euphoria, confusion, psychotic reactions, nystagmus, vertigo, dizziness, asthenia, headache and drowsiness.</li></ul></li><li>Cardiac — circulatory collapse.</li><li>Skin — angioneurotic oedema, maculopapular, erythematous or eczematous eruptions, urticaria, rash, and pruritus.<ul><li>Rarely: lupus-like syndrome, exfoliative dermatitis and erythema multiforme (including Stevens-Johnson Syndrome).</li></ul></li><li>Musculoskeletal — arthralgia.</li></ul><p><strong>Drug interactions </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">BNF 76, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">FSRH, 2017</a>]</p><ul><li>Alkalinizing agents (such as potassium citrate) — the antibacterial activity of nitrofurantoin is reduced when the pH of the urine is increased. It may be prudent to avoid in people taking nitrofurantoin, however there is no evidence that this possible interaction presents a problem in practice.</li><li>Magnesium trisilicate — absorption of nitrofurantoin may be reduced. </li><li>Oral hormonal contraception — additional contraceptive precautions are not required during or after courses of nitrofurantoin. However, women should be advised about the importance of correct contraceptive practice if they experience vomiting or diarrhoea.<ul><li>For further information, see the sections on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li><li>Amiodarone, isoniazid, lamivudine, metronidazole, phenytoin, stavudine — can increase risk of peripheral neuropathy.</li><li>Dapsone, topical prilocaine — predicted to increase the risk of methaemoglobinaemia.</li><li>Typhoid Vaccine (oral) — antibacterials inactivate oral typhoid vaccine.</li></ul><p><strong>Monitoring</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">BNF 76, 2018</a>]</p><ul><li>Consider checking renal function when treating with nitrofurantoin, especially in the elderly [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">MHRA, 2015</a>].</li><li>Long-term therapy — monitor liver function and for signs of pulmonary adverse effects, especially in the elderly (discontinue if deterioration in lung function).</li><li>Chronic pulmonary reactions (including pulmonary fibrosis and diffuse interstitial pneumonitis) can develop insidiously, and may occur commonly in elderly patients.</li></ul><p><strong>Pregnancy and breastfeeding</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">ACOG, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">BNF 76, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">EAU, 2018</a>]</p><ul><li><strong>Pregnancy</strong><ul><li>Nitrofurantoin is not known to be harmful in pregnancy, however clinical guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">NICE, 2018d</a>] and the BNF recommend that nitrofurantoin should be avoided at term, because of the risk of neonatal haemolysis. This includes women with threatened pre-term labour [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">All Wales Medicines Strategy Group, 2018</a>].</li></ul></li><li><strong>Breastfeeding</strong><ul><li>Nitrofurantoin is excreted in small amounts in breastmilk. Avoid breastfeeding during treatment with nitrofurantoin if the newborn is glucose-6-phosphate dehydrogenase deficient.</li></ul></li></ul><!-- end field 22e6a413-a978-4ea4-b337-a71c00ac3fdb --><!-- end item 7ad0b6b8-162a-4f7e-a3df-a71c00ac3fe5 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}